Shenzhen Edge Medical Co., Ltd. (Edge Medical) has published its first Environmental, Social and Governance (ESG) Report, covering operations from 1 January to 31 December 2025 and approved by the Board on 27 March 2026. Prepared in accordance with Hong Kong Stock Exchange Appendix C2 requirements, the report outlines the company’s governance structure, sustainability targets and performance across environmental, social and product-responsibility dimensions.
Edge Medical highlights a three-tier ESG governance framework led by its nine-member Board, with management and an ESG Working Group responsible for execution. Key issues identified through a materiality assessment include product quality and safety, business ethics, technological innovation, occupational health and safety, and customer service.
Product quality remained a central theme: the company operates an ISO 13485-certified quality management system that spans design, manufacturing and post-market surveillance. No product recalls were recorded in 2025, and all three customer complaints received during the year were resolved, achieving a 100% closure rate.
Technological innovation continues to underpin growth. Edge Medical invested in seven proprietary platform technologies and reported 736 granted patents worldwide. During 2025 the company obtained CE marking for its MP1000 and SP1000 surgical robots, secured Mexico’s COFEPRIS and Brazil’s ANVISA approvals, and launched the CP1000 bronchoscope robot in China. Strategic alliances were formed with partners in Europe, Poland, Southeast Asia and the Middle East, while installations were completed in Nigeria and Uzbekistan.
On the environmental front, total greenhouse-gas emissions reached 1,569.05 tCO₂e, comprising 36.62 tCO₂e (Scope 1), 905.82 tCO₂e (Scope 2) and 626.61 tCO₂e (partial Scope 3). Emission intensity was 3.44 tCO₂e per RMB million of revenue. Energy consumption stood at 223.32 tce, driven mainly by 1.71 million kWh of purchased electricity. Wastewater discharge totalled 4 tonnes, while 0.85 tonnes of hazardous waste and 7.15 tonnes of non-hazardous waste were generated, all disposed of in compliance with regulations. The company targets a 20% reduction in water-intensity by 2030 (base year 2024) and reports achieving 100% compliance in wastewater discharge and hazardous-waste treatment for 2025.
Edge Medical employed 602 staff at year-end, with women accounting for 30.23% of the workforce. Employee turnover was 26.24% overall, and 410 employees—71.02% of general staff and 22.22% of middle and senior managers—received training averaging 7.32 hours per person. The company reported zero work-related fatalities over the past three years and 42 lost workdays in 2025.
Supply-chain oversight covers 206 suppliers, 100% of whom have signed integrity clauses. Environmental criteria such as ISO 14001 certification and RoHS compliance are incorporated into supplier evaluations, and no supplier-related quality incidents occurred during the reporting period.
Edge Medical’s 2026 outlook calls for continued product expansion, deeper global market penetration, strengthened employee development and further integration of low-carbon practices, including greener manufacturing and broader use of recycled materials. The company also plans to extend remote-surgery capabilities to increase access to advanced medical care in underserved regions.
Comments